Contact Us
Subscribe
e-Edition

Dashboard
Logout

- My Account
- Dashboard
- Profile
- Saved items
- Logout

Facebook
Twitter
YouTube

48°
- Broken Bow, NE (68822)
  Today
  
  Windy with a mix of clouds and sun this morning then becoming cloudy this afternoon. High around 55F. Winds NNE at 20 to 30 mph. Winds could occasionally gust over 40 mph..
  
  Tonight
  
  Cloudy. Low 32F. Winds ENE at 10 to 15 mph.
  
  Updated: March 31, 2026 @ 12:05 pm
- Full Forecast

Site search

Home
News
- Local News
Sports
Obituaries
Photos
Videos
e-Edition
Classifieds
- Legal Notices
Business Directory

Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

REGENXBIO Inc. - Common Stock (NQ:RGNX)

8.340 +0.570 (+7.34%)

Streaming Delayed Price Updated: 1:10 PM EDT, Mar 31, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about REGENXBIO Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >

Benzinga's Top Ratings Upgrades, Downgrades For June 23, 2022 ↗

June 23, 2022

Upgrades

Via Benzinga

Expert Ratings for Regenxbio ↗

May 05, 2022

Regenxbio (NASDAQ:RGNX) has observed the following analyst ratings within the last quarter:

Via Benzinga

Regenxbio: Q4 Earnings Insights ↗

March 01, 2022

Regenxbio (NASDAQ:RGNX) reported its Q4 earnings results on Tuesday, March 1, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Regenxbio...

Via Benzinga

Earnings Scheduled For March 1, 2022 ↗

March 01, 2022

Companies Reporting Before The Bell • Precigen (NASDAQ:PGEN) is expected to report earnings for its fourth quarter. • TG Therapeutics (NASDAQ:TGTX) is estimated...

Via Benzinga

5 Small-Cap S&P Stocks To Buy With The Most Upside ↗

May 26, 2022

The S&P 500 is one of the most popular U.S. stock indices and is often what investors and experts are referring to when they mention the "stock market." However, there's more to the market than...

Via Benzinga

Regenxbio's Return On Capital Employed Overview ↗

May 24, 2022

Regenxbio (NASDAQ:RGNX) brought in sales totaling $22.22 million during Q1 according to data provided by Benzinga Pro. However, earnings decreased 126.09%, resulting in a loss of $76.72 million.

Via Benzinga

Expert Ratings for Regenxbio ↗

May 24, 2022

Over the past 3 months, 4 analysts have published their opinion on Regenxbio (NASDAQ:RGNX) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a...

Via Benzinga

The Daily Biotech Pulse: Pfizer-BioNTech's COVID-19 Booster For Kids 5-11 Coming Soon, Ultragenyx In-Licenses Gene Therapy For Genetic Disorder, Ampio's AP-013 Trial Under Independent Investigation ↗

May 17, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Earnings Preview: Regenxbio ↗

February 28, 2022

Regenxbio (NASDAQ:RGNX) is set to give its latest quarterly earnings report on Tuesday, 2022-03-01. Here's what investors need to know before the announcement. Analysts estimate...

Via Benzinga

RegenXBio Posts Updated Data From Hunter Syndrome Gene Therapy Trial ↗

February 09, 2022

Regenxbio Inc (NASDAQ: RGNX) announced

Via Benzinga

Expert Ratings For Regenxbio ↗

January 28, 2022

Over the past 3 months, 4 analysts have published their opinion on Regenxbio (NASDAQ:RGNX) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a...

Via Benzinga

5 Value Stocks In The Healthcare Sector ↗

May 16, 2022

What are Value Stocks? A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E multiples are good base indicators...

Via Benzinga

The Week Ahead In Biotech: Gene & Cell Therapy Conference, Tapering Earnings News, OKYO Pharma IPO And More ↗

May 16, 2022

Biopharma stocks remained largely unchanged in the week ending May 13, with the defensive nature of the sector coming to its aid. Stocks reacted to the broader market move and earnings news from...

Via Benzinga

12 Health Care Stocks Moving In Friday's After-Market Session ↗

May 06, 2022

Gainers Kiromic BioPharma (NASDAQ:KRBP) stock increased by 12.6% to $0.58 during Friday's after-market session. The market value of their outstanding shares is at $8.9 million.

Via Benzinga

83 Biggest Movers From Yesterday ↗

May 06, 2022

Gainers Hudson Technologies, Inc. (NASDAQ: HDSN) shares jumped 26.9% to close at $9.06 on Thursday after the company reported better-than-expected Q1 EPS and sales results.

Via Benzinga

57 Stocks Moving In Thursday's Mid-Day Session ↗

May 05, 2022

Gainers

Via Benzinga

The Daily Biotech Pulse: Kezar Life's Lead Asset Fails, Brickell Biotech Offloads Late-Stage Asset, Connect Biopharma Ulcerative Colitis Trial Disappoints ↗

May 04, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours.

Via Benzinga

7 Top-Rated Biotech Stocks to Buy for Q2 ↗

April 21, 2022

In these tumultous economic times, look to sectors that are outside the turmoil. Each of these seven biotech stocks fit the bill.

Via InvestorPlace

Regenxbio's Return On Capital Employed Overview ↗

March 07, 2022

According to Benzinga Pro, during Q4, Regenxbio (NASDAQ:RGNX) earned $294.02 million, a 603.42% increase from the preceding quarter. Regenxbio also posted a total of $398.65...

Via Benzinga

Expert Ratings For Regenxbio ↗

March 02, 2022

Over the past 3 months, 4 analysts have published their opinion on Regenxbio (NASDAQ:RGNX) stock. These analysts are typically employed by large Wall Street banks and tasked with...

Via Benzinga

The Daily Biotech Pulse: Karyopharm Flags Delay In Selinexor Label Expansion, Finch, Celyad Hit With Clinical Holds, Adagene Strikes R&D Collaboration With Sanofi ↗

March 02, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Karyopharm Says FDA Mandates Additional Study For Expanding Selinexor Label...

Via Benzinga

The Daily Biotech Pulse: Legend Biotech, CTI Biopharma Receive FDA Approvals, AbbVie Announces Delay In Skyrizi Review, Editas Gains On CRISPR Patent Resolution ↗

March 01, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Editas Gains On Resolution Of CRISPR Gene Editing Patent Case Editas Medicine...

Via Benzinga

The Week Ahead In Biotech (Feb. 27-March 5): Earnings, Multiple Regulatory Decisions Take The Spotlight ↗

February 27, 2022

Biopharma stocks lock-stepped with the broader market in the week ending Feb. 25 before finishing higher. The trajectory was the same, with the sector declining in the first...

Via Benzinga

The Daily Biotech Pulse: Bristol-Myers Squibb Announces $5B Accelerated Buyback, Qiagen Reaps COVID Testing Windfall, WORLDSymposium Presentations Kick In ↗

February 09, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

The Week Ahead In Biotech (Feb. 6-12): Pfizer, AstraZeneca Earnings, Conference Presentations, & More ↗

February 06, 2022

Biotech stocks managed to close the week with gains. Stocks recovered along with the broader markets early in the week, but came under pressure midweek amid some big pharma earnings. The sector came...

Via Talk Markets

The Week Ahead In Biotech (Feb. 6-12): Pfizer, AstraZeneca Earnings, Conference Presentations, IPOs And More ↗

February 06, 2022

Biotech stocks managed to close the week ending Feb. 4 with gains. Stocks recovered along with the broader markets early in the week, but came under pressure midweek amid negative reaction to some big...

Via Benzinga

RegenXbio's Duchenne Gene Therapy Secures FDA Orphan Drug Tag ↗

November 22, 2021

The FDA has granted Orphan Drug Designation to RegenXbio Inc's (NASDAQ: RGNX) RGX-202, potential one-time gene therapy for Duchenne muscular dystrophy (...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For December 15, 2021 ↗

December 15, 2021

Upgrades B of A Securities upgraded the previous rating for ONE Gas Inc (NYSE:

Via Benzinga

70 Biggest Movers From Yesterday ↗

November 16, 2021

Gainers Casper Sleep Inc. (NYSE: CSPR) shares jumped 88.5% to close at $6.69 on Monday after the company agreed to be acquired by Durational Capital Management. The...

Via Benzinga

The Daily Biotech Pulse: J&J To Spin-off Consumer Health Business, AstraZeneca Earnings, Embattled Emergent To Buy Back Shares ↗

November 12, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus J&J to Separate Its Consumer Health Business Into a New Publicly Traded...

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Sections

Home
News
Sports
Business
Entertainment
Local Events
Obituaries
Multimedia
Online Features

Services

Subscription Services
Pay Your Bill
Classifieds
Promote Your Event
Email Alerts
Place an Ad
Rack Locations
Search
Weather

custercountychief.com
311 South 10th Avenue
Broken Bow, NE 68822
Phone: 308-872-2471
Email: publisher@custercountychief.com

Facebook
Twitter
YouTube

Browser Compatibility

Your browser is out of date and potentially vulnerable to security risks.
We recommend switching to one of the following browsers:

Microsoft Edge Google Chrome Firefox

Broken Bow, NE (68822)

Today

Tonight

REGENXBIO Inc. - Common Stock (NQ:RGNX)

All News about REGENXBIO Inc. - Common Stock

Sections

Services

Follow Us